[Clinical evaluation of cetirizine].
Efficiency of cetirizine--a new antihistaminic agent--was evaluated in 61 patients with seasonal rhinitis in placebo-controlled double-blind trial. Patients were randomly divided into subgroups. Cetirizine significantly inhibited the symptoms of allergic rhinitis and conjunctivitis. Adverse reactions were similar to those of placebo. Increased clinical efficiency but also an increase in adverse reaction incidence were noted when the drug was administered in the evening and not in the morning. High efficacy of placebo is worth mentioning. Therefore, antihistaminic agents should be tested in placebo-controlled double-blind trials.
Tarchalska-Kryńska
B
B
Z Zakładu Farmakologii Doświadczalnej i Klinicznej.
Zawisza
E
E
D000293:Adolescent; D000328:Adult; D017332:Cetirizine; D002648:Child; D004311:Double-Blind Method; D005260:Female; D006634:Histamine H1 Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D006919:Hydroxyzine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010919:Placebos; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*
D006634:Histamine H1 Antagonists; D010919:Placebos; D006919:Hydroxyzine; D017332:Cetirizine